Inogen (INGN) 10-Q 8 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	INGN
Entity Registrant Name	INOGEN, INC.
Entity Central Index Key	0001294133
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		23,194,473
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity File Number	001-36309
Entity Tax Identification Number	33-0989359
Entity Address, Address Line One	301 Coromar Drive
Entity Address, City or Town	Goleta
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	(805)
Local Phone Number	562-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 167,687	$ 187,014
Marketable securities	2,459
Accounts receivable, net	51,135	62,725
Inventories, net	30,744	34,093
Income tax receivable	1,821	1,626
Prepaid expenses and other current assets	15,377	19,187
Total current assets	269,223	304,645
Property and equipment, net	49,195	43,269
Goodwill	32,889	32,852
Operating lease right-of-use asset	20,267	21,653
Other assets	2,777	2,622
Total assets	374,351	405,041
Current liabilities
Accounts payable and accrued expenses	27,612	33,974
Accrued payroll	10,835	11,190
Warranty reserve - current	8,602	7,790
Operating lease liability - current	3,622	3,515
Deferred revenue - current	8,696	8,880
Total current liabilities	59,367	65,349
Long-term liabilities
Warranty reserve - noncurrent	12,596	12,123
Operating lease liability - noncurrent	18,257	19,764
Deferred revenue - noncurrent	9,352	10,399
Total liabilities	99,572	107,635
Commitments and contingencies (Note 9)
Stockholders' equity
Common stock, $0.001 par value per share; 200,000,000 authorized; 23,194,034 and 22,941,643 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	23	23
Additional paid-in capital	319,357	312,126
Accumulated deficit	(44,675)	(14,500)
Accumulated other comprehensive income (loss)	74	(243)
Total stockholders' equity	274,779	297,406
Total liabilities and stockholders' equity	$ 374,351	$ 405,041

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	23,194,034	22,941,643
Common stock, shares outstanding	23,194,034	22,941,643

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Sales revenue	$ 68,343	$ 89,291	$ 124,230	$ 156,693
Rental revenue	15,292	14,085	31,567	27,068
Total revenue	83,635	103,376	155,797	183,761
Cost of revenue
Cost of sales revenue	42,028	50,661	75,992	90,161
Cost of rental revenue, including depreciation of $3,238 and $2,720, for the three months ended and $6,316 and $5,358 for the six months ended, respectively	7,563	6,457	15,028	12,336
Total cost of revenue	49,591	57,118	91,020	102,497
Gross profit
Gross profit-sales revenue	26,315	38,630	48,238	66,532
Gross profit-rental revenue	7,729	7,628	16,539	14,732
Total gross profit	34,044	46,258	64,777	81,264
Operating expense
Research and development	4,293	6,064	9,637	11,428
Sales and marketing	26,906	30,388	55,347	58,427
General and administrative	14,613	12,682	33,476	27,871
Total operating expense	45,812	49,134	98,460	97,726
Loss from operations	(11,768)	(2,876)	(33,683)	(16,462)
Other income (expense)
Interest income	1,646	225	3,171	254
Other income (expense)	337	(722)	574	(1,155)
Total other income (expense), net	1,983	(497)	3,745	(901)
Loss before provision for income taxes	(9,785)	(3,373)	(29,938)	(17,363)
Provision for income taxes	41	69	237	293
Net loss	(9,826)	(3,442)	(30,175)	(17,656)
Other comprehensive income (loss), net of tax
Change in foreign currency translation adjustment	7	(634)	177	(837)
Change in net unrealized gains (losses) on foreign currency hedging	7	(1,204)	7	(1,878)
Less: reclassification adjustment for net (gains) losses included in net income		606		1,206
Total net change in unrealized gains (losses) on foreign currency hedging	7	(598)	7	(672)
Change in net unrealized gains (losses) on marketable securities	64	7	133	(1)
Total other comprehensive income (loss), net of tax	78	(1,225)	317	(1,510)
Comprehensive loss	$ (9,748)	$ (4,667)	$ (29,858)	$ (19,166)
Basic net loss per share attributable to common stockholders (Note 6)	$ (0.42)	$ (0.15)	$ (1.31)	$ (0.77)
Diluted net loss per share attributable to common stockholders (Note 6)	$ (0.42)	$ (0.15)	$ (1.31)	$ (0.77)
Weighted average number of shares used in calculating net loss per share attributable to common stockholders:
Basic common shares	23,146,117	22,845,040	23,078,244	22,799,981
Diluted common shares	23,146,117	22,845,040	23,078,244	22,799,981

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Depreciation	$ 3,238	$ 2,720	$ 6,316	$ 5,358

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2021	$ 370,227	$ 23	$ 299,463	$ 69,272	$ 1,469
Beginning Balance, shares at Dec. 31, 2021		22,731,586
Stock-based compensation	5,685		5,685
Employee stock purchases	915		915
Employee stock purchases, shares		30,558
Restricted stock awards issued, net of forfeitures, shares		(5,011)
Vesting of restricted stock units	(1,062)		(1,062)
Vesting of restricted stock units, shares		102,716
Shares withheld related to net restricted stock settlement	(97)		(97)
Shares withheld related to net restricted stock settlement, shares		(2,783)
Stock options exercised	35		35
Stock options exercised, shares		8,649
Net loss	(17,656)			(17,656)
Other comprehensive income	(1,510)				(1,510)
Ending Balance at Jun. 30, 2022	356,537	$ 23	304,939	51,616	(41)
Ending Balance, shares at Jun. 30, 2022		22,865,715
Beginning Balance at Mar. 31, 2022	358,285	$ 23	302,020	55,058	1,184
Beginning Balance, shares at Mar. 31, 2022		22,836,472
Stock-based compensation	3,020		3,020
Restricted stock awards issued, net of forfeitures, shares		(5,011)
Vesting of restricted stock units	(104)		(104)
Vesting of restricted stock units, shares		29,221
Shares withheld related to net restricted stock settlement	(3)		(3)
Shares withheld related to net restricted stock settlement, shares		(117)
Stock options exercised	6		6
Stock options exercised, shares		5,150
Net loss	(3,442)			(3,442)
Other comprehensive income	(1,225)				(1,225)
Ending Balance at Jun. 30, 2022	356,537	$ 23	304,939	51,616	(41)
Ending Balance, shares at Jun. 30, 2022		22,865,715
Beginning Balance at Dec. 31, 2022	297,406	$ 23	312,126	(14,500)	(243)
Beginning Balance, shares at Dec. 31, 2022		22,941,643
Stock-based compensation	6,705		6,705
Employee stock purchases	630		630
Employee stock purchases, shares		47,676
Vesting of restricted stock units	(487)		(487)
Vesting of restricted stock units, shares		150,778
Shares withheld related to net restricted stock settlement	(1)		(1)
Shares withheld related to net restricted stock settlement, shares		(495)
Stock options exercised	$ 384		384
Stock options exercised, shares	54,432	54,432
Net loss	$ (30,175)			(30,175)
Other comprehensive income	317				317
Ending Balance at Jun. 30, 2023	274,779	$ 23	319,357	(44,675)	74
Ending Balance, shares at Jun. 30, 2023		23,194,034
Beginning Balance at Mar. 31, 2023	281,297	$ 23	316,127	(34,849)	(4)
Beginning Balance, shares at Mar. 31, 2023		23,120,786
Stock-based compensation	3,263		3,263
Vesting of restricted stock units	(33)		(33)
Vesting of restricted stock units, shares		73,248
Net loss	(9,826)			(9,826)
Other comprehensive income	78				78
Ending Balance at Jun. 30, 2023	$ 274,779	$ 23	$ 319,357	$ (44,675)	$ 74
Ending Balance, shares at Jun. 30, 2023		23,194,034

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (30,175)	$ (17,656)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,394	11,608
Loss on rental units and other assets	2,138	1,466
Gain on sale of former rental assets	(40)	(93)
Provision for sales revenue returns and doubtful accounts	4,488	6,200
Provision for inventory losses	989	1,552
Stock-based compensation expense	6,705	5,685
Change in fair value of earnout liability		(1,411)
Changes in operating assets and liabilities:
Accounts receivable	7,145	(13,788)
Inventories	1,143	(2,623)
Income tax receivable	(187)	(327)
Prepaid expenses and other current assets	3,813	482
Operating lease right-of-use asset	1,391	1,428
Other noncurrent assets	91	87
Accounts payable and accrued expenses	(6,456)	281
Accrued payroll	(358)	(4,637)
Warranty reserve	1,285	778
Deferred revenue	(1,231)	(27)
Income tax payable		(82)
Operating lease liability	(1,406)	(1,490)
Net cash used in operating activities	(2,271)	(12,567)
Cash flows from investing activities
Maturities of available-for-sale securities	10,500	9,988
Purchases of available-for-sale securities	(12,826)
Investment in intangible assets	(494)
Investment in property and equipment	(3,116)	(2,236)
Production and purchase of rental equipment	(11,810)	(7,083)
Proceeds from sale of former assets	96	153
Net cash provided by (used in) investing activities	(17,650)	822
Cash flows from financing activities
Proceeds from stock options exercised	384	35
Proceeds from employee stock purchases	630	915
Payment of employment taxes related to release of restricted stock	(488)	(1,159)
Net cash provided by (used in) financing activities	526	(209)
Effect of exchange rates on cash	68	51
Net decrease in cash and cash equivalents	(19,327)	(11,903)
Cash and cash equivalents, beginning of period	187,014	235,524
Cash and cash equivalents, end of period	167,687	223,621
Supplemental disclosures of cash flow information
Cash paid during the period for income taxes, net of refunds received	420	483
Supplemental disclosure of non-cash transactions
Property and equipment in accounts payable and accrued liabilities	$ 115	$ 345

Business Overview

Business Overview	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	1. Business overview Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology business that primarily develops, manufactures and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company refers to as the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One® and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on April 13, 2017 . On May 4, 2017, Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V. (MedSupport) and began operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V. on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. Inogen completed the acquisition of New Aera, Inc. (New Aera) on August 9, 2019.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of presentation and summary of significant accounting policies The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The results of operations for the three and six months ended June 30, 2023 shown in this report are not necessarily indicative of results to be expected for the full year ending December 31, 2023. In the opinion of the Company’s management, the information contained herein reflects all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the Company’s results of operations, financial position, cash flows and stockholders’ equity. Certain footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2023. Except as further described below, there have been no significant changes in the Company’s accounting policies from those disclosed in its Annual Report on Form 10-K filed with the SEC on February 24, 2023. Basis of consolidation The consolidated financial statements include the accounts of Inogen, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of goodwill, impairment of long-lived assets, stock-based compensation expense, and income taxes. Actual results could differ from these estimates. Restructuring charges Restructuring costs include workforce reductions, termination benefits, centralizing manufacturing activities, outsourcing, contract termination, and equipment relocation. Key assumptions used in calculating the restructuring costs include the terms of, and payments under, agreements to terminate certain contractual obligations and the timing of reductions in workforce .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair value measurements Cash, cash equivalents and marketable securities The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis for cash, cash equivalents and marketable securities: As of June 30, 2023 Gross Cash Adjusted unrealized and cash Marketable cost gains Fair value equivalents securities Cash $ 27,692 $ — $ 27,692 $ 27,692 $ — Level 1: Money market accounts 99,504 — 99,504 99,504 — Level 2: U.S. Treasury securities 22,218 160 22,378 19,919 2,459 Institutional Insured Liquidity Deposit Savings 20,572 — 20,572 20,572 — Total $ 169,986 $ 160 $ 170,146 $ 167,687 $ 2,459 As of December 31, 2022 Gross Cash Adjusted unrealized and cash cost gains Fair value equivalents Cash $ 27,970 $ — $ 27,970 $ 27,970 Level 1: Money market accounts 113,534 — 113,534 113,534 Level 2: Corporate bonds 6,474 — 6,474 6,474 U.S. Treasury securities 18,913 26 18,939 18,939 Institutional Insured Liquidity Deposit Savings 20,097 — 20,097 20,097 Total $ 186,988 $ 26 $ 187,014 $ 187,014 Derivative instruments and hedging activities The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheet. The Company had a related receivable of $ 179 and payable of $ 422 as of June 30, 2023 and December 31, 2022, respectively. Accumulated other comprehensive income (loss) The components of accumulated other comprehensive income (loss) were as follows: Foreign Unrealized Unrealized Accumulated currency gains gains other translation on marketable on cash comprehensive adjustments securities flow hedges income (loss) Balance as of December 31, 2022 $ ( 269 ) $ 26 $ — $ ( 243 ) Other comprehensive income 177 133 7 317 Balance as of June 30, 2023 $ ( 92 ) $ 159 $ 7 $ 74 Comprehensive income (loss) is the total net earnings and all other non-owner changes in equity. Except for foreign currency translation adjustments and unrealized gains and losses on marketable securities, the Company does not have any transactions or other economic events that qualify as other comprehensive income (loss).

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance sheet components Cash, cash equivalents and marketable securities Cash, cash equivalents and marketable securities consist of the following: June 30, December 31, Cash and cash equivalents 2023 2022 Cash $ 27,692 $ 27,970 Money market accounts 99,504 113,534 Corporate bonds — 6,474 U.S. Treasury securities 19,919 18,939 Institutional Insured Liquidity Deposit Savings 20,572 20,097 Total cash and cash equivalents $ 167,687 $ 187,014 Marketable securities U.S. Treasury securities 2,459 — Total marketable securities $ 2,459 $ — Accounts receivable and allowance for bad debts, returns, and adjustments Net accounts receivable (gross accounts receivable, net of allowances) balance concentrations by major category as of June 30, 2023 and December 31, 2022 were as follows: June 30, December 31, Net accounts receivable 2023 2022 Rental (1) $ 5,886 $ 5,246 Business-to-business and other receivables (2) 45,249 57,479 Total net accounts receivable $ 51,135 $ 62,725 (1) Rental includes Medicare, Medicaid/other government, private insurance and patient pay. (2) Business-to-business receivables included extended terms for two customers: 1) One customer had accounts receivable balances of $ 5,878 and $ 9,861 as of June 30, 2023 and December 31, 2022 , respectively. The customer received extended payment terms through a direct financing plan offered. The Company also has a credit insurance policy in place, which allocated up to $ 12,000 in coverage as of June 30, 2023 and December 31, 2022 , for this customer with a $ 400 deductible and 10 % retention; and 2) One customer had an accounts receivable balance of $ 14,421 and $ 22,641 as of June 30, 2023 and December 31, 2022 . The following table sets forth the accounts receivable allowances as of June 30, 2023 and December 31, 2022: June 30, December 31, Allowances - accounts receivable 2023 2022 Doubtful accounts $ 236 $ 77 Sales returns 684 483 Total allowances - accounts receivable $ 920 $ 560 Concentration of customers and vendors The Company primarily sells its products to traditional home medical equipment providers, distributors, and resellers in the United States and in foreign countries on a credit basis. The Company also sells its products direct-to-consumers primarily on a prepayment basis. Two customers each represented more than 10% of the Company’s net accounts receivable balance with accounts receivable balances of $ 14,421 and $ 5,878 , respectively, as of June 30, 2023 , and two customers each represented more than 10% of the Company's net accounts receivable balance with accounts receivable balances of $ 22,641 and $ 9,861 , respectively, as of December 31, 2022. The Company also rents products directly to consumers for insurance reimbursement, which resulted in a customer concentration relating to Medicare’s service reimbursement programs. Medicare’s service reimbursement programs accounted for 72.1 % and 78.5 % of rental revenue in the six months ended June 30, 2023 and 2022 , respectively, and based on total revenue were 14.6 % and 11.6 % for the six months ended June 30, 2023 and 2022 , respectively. Accounts receivable balances relating to Medicare’s service reimbursement programs (including held and unbilled, net of allowances) amounted to $ 2,143 or 4.2 % of total net accounts receivable as of June 30, 2023 compared to $ 2,138 or 3.4 % of total net accounts receivable as of December 31, 2022. The Company currently purchases raw materials from a limited number of vendors, which resulted in a concentration of three major vendors. The three major vendors supply the Company with raw materials used to manufacture the Company’s products. For the six months ended June 30, 2023 , the Company’s three major vendors accounted for 30.1 %, 14.5 % and 11.0 %, respectively, of total raw material purchases. For the six months ended June 30, 2022 , the Company’s three major vendors accounted for 24.4 %, 22.3 % and 8.8 %, respectively, of total raw material purchases. A portion of revenue is earned from sales outside the United States. Approximately 80.0 % and 77.4 % of the non-U.S. revenue for the three months ended June 30, 2023 and 2022 , respectively, were invoiced in Euros. Approximately 78.7 % and 75.6 % of the non-U.S. revenue for the six months ended June 30, 2023 and 2022, respectively, were invoiced in Euros. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the three and six months ended June 30, 2023 and 2022, respectively, is as follows: Three months ended Six months ended 2023 2022 2023 2022 U.S. revenue $ 60,343 $ 65,935 $ 113,533 $ 118,379 Non-U.S. revenue 23,292 37,441 42,264 65,382 Total revenue $ 83,635 $ 103,376 $ 155,797 $ 183,761 Inventories Inventories are stated at the lower of cost and net realizable value, using the first-in, first-out (FIFO) method. The Company records adjustments at least quarterly to inventory for potentially excess, obsolete, slow-moving or impaired items. The Company recorded noncurrent inventory related to inventories that are expected to be realized or consumed after one year of $ 1,087 and $ 1,249 as of June 30, 2023 and December 31, 2022 , respectively. Noncurrent inventories are primarily related to raw materials purchased in bulk to support long-term expected repairs to reduce costs and are classified in other assets. The Company had prepayments for raw materials of $ 2,369 and $ 7,017 as of June 30, 2023 and December 31, 2022, respectively, that were classified in prepaid expenses and other current assets. During the six months ended June 30, 2023 and 2022 , $ 1,567 and $ 692 , respectively, of inventory was transferred to rental equipment and was considered a noncash transaction in the production and purchase of rental equipment on the consolidated statements of cash flows. Inventories that are considered current consist of the following: June 30, December 31, 2023 2022 Raw materials and work-in-progress $ 22,100 $ 26,496 Finished goods 10,231 9,324 Less: reserves ( 1,587 ) ( 1,727 ) Inventories, net $ 30,744 $ 34,093 Property and equipment Repair and maintenance expense, which includes labor, parts and freight, for rental equipment was $ 1,241 and $ 1,201 for the three months ended June 30, 2023 and 2022 , respectively, and $ 2,553 and $ 2,230 for the six months ended June 30, 2023 and 2022, respectively. Depreciation and amortization expense related to rental equipment and other property and equipment are summarized below for the three and six months ended June 30, 2023 and 2022, respectively. Three months ended Six months ended 2023 2022 2023 2022 Rental equipment $ 3,238 $ 2,720 $ 6,316 $ 5,358 Other property and equipment 1,017 978 1,999 1,953 Total depreciation and amortization $ 4,255 $ 3,698 $ 8,315 $ 7,311 Property and equipment and rental equipment with associated accumulated depreciation is summarized below as of June 30, 2023 and December 31, 2022, respectively. June 30, December 31, Property and equipment 2023 2022 Rental equipment, net of allowances of $ 2,885 and $ 2,255 , respectively $ 65,603 $ 61,679 Other property and equipment 36,494 33,434 Property and equipment 102,097 95,113 Accumulated depreciation Rental equipment 30,535 31,320 Other property and equipment 22,367 20,524 Accumulated depreciation 52,902 51,844 Property and equipment, net Rental equipment, net of allowances of $2,885 and $2,255, respectively 35,068 30,359 Other property and equipment 14,127 12,910 Property and equipment, net $ 49,195 $ 43,269 Long-lived assets The Company accounts for the impairment and disposition of long-lived assets in accordance with Accounting Standards Codification (ASC) 360 — Property, Plant, and Equipment . In accordance with ASC 360, long-lived assets to be held are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. No impairments were recorded as of June 30, 2023 and June 30, 2022. Goodwill The changes in the carrying amount of goodwill for the six months ended June 30, 2023 were as follows: Balance as of December 31, 2022 $ 32,852 Translation adjustment 37 Balance as of June 30, 2023 $ 32,889 As of June 30, 2023 , the Company had no accumulated impairment losses related to goodwill. Current liabilities Accounts payable and accrued expenses as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, 2023 2022 Accounts payable $ 13,389 $ 18,237 Accrued inventory (in-transit and unvouchered receipts) and trade payables 7,913 10,837 Accrued purchasing card liability 4,065 2,606 Accrued franchise, sales and use taxes 482 492 Other accrued expenses 1,763 1,802 Accounts payable and accrued expenses $ 27,612 $ 33,974 Accrued payroll as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, 2023 2022 Accrued bonuses $ 1,661 $ 2,620 Accrued wages and other payroll related items 5,664 4,967 Accrued vacation 3,099 3,133 Accrued employee stock purchase plan deductions 411 470 Accrued payroll $ 10,835 $ 11,190

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	5. Leases The Company has entered into operating leases primarily for commercial buildings. These leases have terms which range from 3 years to 11 years , some of which include options to extend the leases for up to 5 years . Rent expense, including short-term lease cost, was $ 964 and $ 958 for the three months ended June 30, 2023 and 2022 , respectively, and $ 1,936 and $ 1,929 for the six months ended June 30, 2023 and 2022, respectively. Information related to the Company's right-of-use assets and related operating lease liabilities were as follows: Six months ended June 30, 2023 2022 Cash paid for operating lease liabilities $ 1,986 $ 1,994 Operating lease cost 1,920 1,932 Non-cash right-of-use assets obtained in exchange for new operating lease obligations 264 225 Weighted average remaining lease term 2.0 years 2.7 years Weighted average discount rate 3.0 % 2.9 % Maturities of lease liabilities due in the 12-month period ending June 30, 2024 $ 4,030 2025 3,149 2026 2,778 2027 2,813 2028 2,845 Thereafter 7,967 23,582 Less imputed interest ( 1,703 ) Total lease liabilities $ 21,879 Operating lease liability - current $ 3,622 Operating lease liability - noncurrent $ 18,257 Total lease liabilities $ 21,879

Earnings (Loss) per Share

Earnings (Loss) per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings (Loss) per Share	6. Earnings (loss) per share Earnings (loss) per share (EPS) is computed in accordance with ASC 260 —Earnings per Share and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents (which can include dilution of outstanding stock options, restricted stock units and restricted stock awards) unless the effect is to reduce a loss or increase the income per share. For purposes of this calculation, common stock subject to repurchase by the Company, options, and other dilutive awards are considered to be common stock equivalents and are only included in the calculation of diluted earnings (loss) per share when their effect is dilutive. The computation of EPS is as follows: Three months ended Six months ended 2023 2022 2023 2022 Numerator—basic and diluted: Net loss $ ( 9,826 ) $ ( 3,442 ) $ ( 30,175 ) $ ( 17,656 ) Denominator: Weighted average common shares - basic common stock (1) 23,146,117 22,845,040 23,078,244 22,799,981 Weighted average common shares - diluted common stock (2) 23,146,117 22,845,040 23,078,244 22,799,981 Net loss per share - basic common stock $ ( 0.42 ) $ ( 0.15 ) $ ( 1.31 ) $ ( 0.77 ) Net loss per share - diluted common stock (2) $ ( 0.42 ) $ ( 0.15 ) $ ( 1.31 ) $ ( 0.77 ) Denominator calculation from basic to diluted: Weighted average common shares - basic common stock (1) 23,146,117 22,845,040 23,078,244 22,799,981 Stock options and other dilutive awards 90,017 93,181 211,114 127,759 Weighted average common shares - diluted common stock 23,236,134 22,938,221 23,289,358 22,927,740 Shares excluded from diluted weighted average shares: Stock options 54,498 325,734 54,498 325,734 Restricted stock units and restricted stock awards 1,209,475 509,785 377,931 503,435 Shares excluded from diluted weighted average shares 1,263,973 835,519 432,429 829,169 (1) Unvested restricted stock units and restricted stock awards are not included as shares outstanding in the calculation of basic earnings per share. Vested restricted stock units and restricted stock awards are included in basic earnings per share if all vesting and performance criteria have been met. Performance-based restricted stock units and restricted stock awards are included in the number of shares used to calculate diluted earnings per share as long as all applicable performance criteria are met, and their effect is dilutive. Restricted stock awards are eligible to receive all dividends declared on the Company’s common shares during the vesting period; however, such dividends are not paid until the restrictions lapse. (2) Due to net losses for the three and six months ended June 30, 2023 and June 30, 2022 , diluted loss per share is the same as basic.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	7. Income taxes The Company accounts for income taxes in accordance with ASC 740 — Income Taxes . Under ASC 740, income taxes are recognized for the amount of taxes payable or refundable for the current period and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company’s consolidated financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. As of December 31, 2022, the Company recorded a full valuation allowance of $ 41,933 . As of June 30, 2023, the Company continued to record a valuation allowance against its deferred tax assets. The Company accounts for uncertainties in income taxes in accordance with ASC 740-10 — Accounting for Uncertainty in Income Taxes . ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This accounting standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes interest and penalties on taxes, if any, within its income tax provision on its consolidated statements of comprehensive loss.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ equity The Company has a 2012 Equity Incentive Plan (2012 Plan) under which the Company granted options to purchase shares of its common stock. As of June 30, 2023 , options to purchase 2,866 shares of common stock remained outstanding under the 2012 Plan. The 2012 Plan was terminated in connection with the Company’s initial public offering in February 2014, and accordingly, no new options are available for issuance under this plan. The 2012 Plan continues to govern outstanding awards granted thereunder. The Company has a 2014 Equity Incentive Plan (2014 Plan) under which the Company granted restricted stock units, restricted stock awards, performance units, performance shares and options to purchase shares of its common stock. As of June 30, 2023 , awards with respect to 1,980,633 shares of the Company’s common stock were outstanding. An additional 895,346 shares were added to the 2014 Plan share reserve for 2023. The Company’s stockholders approved the adoption of the 2023 Equity Incentive Plan (2023 Plan) on May 31, 2023 that provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company’s employees and any parent and subsidiary corporation’s employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, restricted stock awards, stock appreciation rights, performance units and performance shares to its employees, directors and consultants and its parent and subsidiary corporations’ employees and consultants. The 2023 Plan became effective June 5, 2023. The 2014 Plan terminated upon effectiveness of the 2023 Plan and no further awards will be made under the 2014 Plan, but the 2014 Plan will continue to govern awards previously granted under it. The number of shares of common stock reserved for issuance under the 2023 Plan was: (i) 400,000 shares, plus (ii) (A) 2,027,790 shares that, as of immediately before the termination or expiration of the 2014 Plan, had been reserved but not issued under any 2014 Plan awards and are not subject to any awards granted under the 2014 Plan, plus (B) any shares subject to awards granted under the 2014 Plan or the 2012 Plan that, after the 2014 Plan is terminated or expired, expire or otherwise terminate without having been exercised or issued in full or are forfeited to or repurchased by the Company due to failure to vest, plus (C) any shares that, after the 2014 Plan is terminated or expired, are tendered to or withheld by us for payment of an exercise or purchase price or for tax withholding obligations with respect to an award granted under the 2014 Plan or 2012 Plan, with the maximum number of shares that may be added to the 2023 Plan under subsection (ii) above equal to 2,950,000 shares. As of June 30, 2023 , 1,255,532 shares of common stock remained available for issuance under the 2023 Plan. The shares available for issuance under the 2023 Plan will be increased by any shares returned to the 2012 Plan and 2014 Plan as a result of 1) expiration or termination of awards and 2) tendered to or withheld by us for payment of an exercise or purchase price or for tax withholding obligations. Stock options Options typically expire between seven and ten years from the date of grant and vest over one to four-year terms. Options have been granted to employees, directors and consultants of the Company, as determined by the board of directors, at the deemed fair market value of the shares underlying the options at the date of grant. The activity for stock options under the Company’s stock plans for the six months ended June 30, 2023 is as follows: Remaining weighted- Weighted- average Per share average contractual average Price per exercise terms intrinsic Options share price (in years) value Outstanding as of December 31, 2022 348,284 $ 1.17 -$ 83.30 $ 44.21 0.43 $ 2.07 Exercised ( 54,432 ) 1.17 - 8.37 7.03 Forfeited ( 4,125 ) 44.19 44.19 Expired ( 232,363 ) 44.19 44.19 Outstanding as of June 30, 2023 57,364 8.37 - 83.30 79.56 0.57 0.16 Vested and exercisable as of June 30, 2023 57,364 8.37 - 83.30 79.56 0.57 0.16 Vested and expected to vest as of June 30, 2023 57,364 $ 8.37 -$ 83.30 $ 79.56 0.57 $ 0.16 The total intrinsic value of options exercised during the six months ended June 30, 2023 and 2022 was $ 735 and $ 204 , respectively. As of June 30, 2023, all stock-based compensation expense for options granted under the Plans was recognized. Stock incentive awards The Company granted restricted stock units (RSUs) and restricted stock awards (RSAs) under the 2014 Plan (Stock Awards). The Stock Awards vest either based solely on the satisfaction of time-based service conditions or on the satisfaction of time-based service conditions combined with performance criteria. Stock Awards are subject to forfeiture if the holder’s services to the Company terminate before vesting. Stock Awards granted with only time-based service vesting conditions generally vest over three-year and four-year service periods, as defined in the terms of each award. Stock Awards that vest based on the satisfaction of time-based service conditions combined with performance criteria generally vest over a three-year service and performance period, based on performance criteria established at the time of the award. The portion of the Stock Award that is earned may equal or be more or less than the targeted number of shares subject to the Stock Award depending on whether the performance criteria are met. Stock Awards activity for the six months ended June 30, 2023 is summarized below: Weighted- average grant Performance date fair and value Restricted stock units Time-based time-based Total per share Unvested restricted stock units as of December 31, 2022 820,941 183,197 1,004,138 $ 32.72 Granted 855,708 536,990 1,392,698 15.11 Vested ( 167,044 ) ( 15,618 ) ( 182,662 ) 35.32 Forfeited/canceled ( 214,852 ) ( 73,185 ) ( 288,037 ) 25.97 Unvested restricted stock units as of June 30, 2023 (1) 1,294,753 631,384 1,926,137 $ 21.20 Unvested and expected to vest restricted stock units outstanding as of June 30, 2023 1,369,435 $ 21.64 Weighted- average grant Performance date fair and value Restricted stock awards Time-based time-based Total per share Unvested restricted stock awards outstanding as of December 31, 2022 786 — 786 $ 59.55 Vested ( 786 ) — ( 786 ) 59.55 Unvested restricted stock awards outstanding as of June 30, 2023 (1) — — — $ — Unvested and expected to vest restricted stock awards outstanding as of June 30, 2023 — $ — (1) Outstanding restricted stock units and restricted stock awards are based on the maximum payout of the targeted number of shares. As of June 30, 2023 , the unrecognized compensation cost related to unvested employee restricted stock units and restricted stock awards was $ 23,037 , excluding estimated forfeitures. This amount is expected to be recognized over a weighted average period of 2.2 years. Employee stock purchase plan The Company’s 2014 Employee Stock Purchase Plan (ESPP) provides for the grant to all eligible employees an option to purchase stock under the ESPP, within the meaning Section 423 of the Internal Revenue Code. The ESPP permits participants to purchase common stock through payroll deductions of up to 15 % of their eligible compensation, which includes a participant’s base straight time gross earnings, incentive compensation, bonuses, overtime and shift premium, but exclusive of payments for equity compensation and other similar compensation. A participant may purchase a maximum of 1,500 shares during a purchase period. Amounts deducted and accumulated by the participant are used to purchase shares of the Company’s common stock at the end of each six-month period. The purchase price of the shares will be 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of each offering period or on the exercise date. The offering periods are currently approximately six months in length beginning on the first business day on or after March 1 and September 1 of each year and ending on the first business day on or after September 1 and March 1 approximately six months later. As of June 30, 2023 , a total of 638,951 shares of common stock were available for sale pursuant to the ESPP. The number of shares available for sale under the ESPP is increased annually on the first day of each fiscal year by an amount equal to the least of: • 179,069 shares; • 1.5 % of the outstanding shares of the Company’s common stock on the last day of the Company’s immediately preceding fiscal year; or • such other amount as may be determined by the administrator. For 2023 , an additional 179,069 shares were added to the ESPP share reserve pursuant to the provision described above. Stock-based compensation Stock-based compensation expense recognized for the three and six months ended June 30, 2023 and 2022, was as follows: Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 3,177 $ 2,891 $ 6,482 $ 5,359 Employee stock purchase plan 86 129 223 326 Total stock-based compensation expense $ 3,263 $ 3,020 $ 6,705 $ 5,685 Employee stock-based compensation expense was calculated based on awards of stock options, restricted stock units and restricted stock awards ultimately expected to vest based on the Company’s historical award cancellations. ASC 718 – Compensation-Stock Compensation requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three and six months ended June 30, 2023 and 2022, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows: Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 Cost of revenue $ 153 $ 303 $ 237 $ 536 Research and development 376 412 834 796 Sales and marketing 658 766 1,432 1,357 General and administrative 2,076 1,539 4,202 2,996 Total stock-based compensation expense $ 3,263 $ 3,020 $ 6,705 $ 5,685

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and contingencies Purchase obligations The Company had approximately $ 124,400 of outstanding purchase orders due within one year with its outside vendors and suppliers as of June 30, 2023. Warranty obligation The following table identifies the changes in the Company’s aggregate product warranty liabilities for the six and twelve-month periods ended June 30, 2023 and December 31, 2022, respectively: June 30, December 31, 2023 2022 Product warranty liability at beginning of period $ 19,913 $ 13,726 Accruals for warranties issued 4,241 10,416 Adjustments related to preexisting warranties 2,817 8,234 Settlements made (in cash or in kind) ( 5,773 ) ( 12,463 ) Product warranty liability at end of period $ 21,198 $ 19,913 Contract liabilities Contract liabilities primarily consist of deferred revenue related to lifetime warranties on direct-to-consumer sales revenue when cash payments are received in advance of services performed under the contract. The contract with the customer states the final terms of the sale, including the description, quantity, and price of each product or service purchase. The decrease in deferred revenue related to lifetime warranties for the six months ended June 30, 2023 was primarily driven by $ 3,309 of revenue recognized that were included in the deferred revenue balances as of December 31, 2022 , partially offset by $ 1,820 of payments received in advance of satisfying performance obligations. Deferred revenue related to lifetime warranties was $ 15,045 and $ 16,534 as of June 30, 2023 and December 31, 2022, respectively, and is classified within deferred revenue - current and noncurrent deferred revenue in the consolidated balance sheet. Legislation and HIPAA The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Compliance with government laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) was enacted to ensure health insurance portability, reduce healthcare fraud and abuse, guarantee security and privacy of health information, and enforce standards for health information. The Health Information Technology for Economic and Clinical Health Act (HITECH Act), in part, imposes notification requirements of certain security breaches relating to protected health information. The Company is not aware of any pending claims against it under the HIPAA and HITECH regulations that are applicable to the Company’s business. Legal proceedings Civil Investigative Demand On June 21, 2022, the Company received a civil investigative demand (CID) from the United States Attorney’s Office for the Northern District of Iowa. The CID states that it was issued in a False Claims Act investigation to determine whether there is or has been a violation of the False Claims Act and that the investigation involves concerns of inappropriate kickbacks provided by certain manufacturers of portable oxygen concentrators and related products in violation of the Anti-Kickback Statute. The CID followed informal requests from the United States Attorney’s Office for the Northern District of Iowa begun in late 2020, with which the Company voluntarily complied, to obtain information concerning the Company’s participation in (i) zero-interest or below market-rate loans through a third party lender to finance customer purchases; (ii) guaranteeing the obligation of a customer to a finance company in connection with financing of purchases of Company equipment; and (iii) entering into an agreement with a customer that included marketing, exclusivity, discount, and favorable financing terms. The Company is cooperating in the investigation. The Company is currently unable to predict the outcome of this investigation or whether qui tam or other litigation is probable. Regardless of the outcome, this inquiry has the potential to have an adverse impact on the Company due to any related defense and settlement costs, diversion of management resources, and other factors. Other Litigation The Company is party to various legal proceedings arising in the normal course of business. The Company carries insurance, subject to specified deductibles under the policies, to protect against losses from certain types of legal claims. At this time, the Company does not anticipate that any of these other proceedings arising in the normal course of business will have a material adverse effect on the Company’s business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Restructuring Charges

Restructuring Charges	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Charges	10. Restructuring charges The Company incurred $ 201 and $ 2,010 of restructuring costs during the three and six months ended June 30, 2023 , respectively, primarily in connection with the Company's cost reduction initiatives, which were recorded within general and administrative expense in the consolidated statements of comprehensive loss. The restructuring charges consisted primarily of severance and termination benefits. Other related costs consisted of targeted workforce reductions, centralizing manufacturing activities, equipment relocation and outsourcing.

Foreign Currency Exchange Contr

Foreign Currency Exchange Contracts and Hedging	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Exchange Contracts and Hedging	11. Foreign currency exchange contracts and hedging As of June 30, 2023 and June 30, 2022 , the Company’s total non-designated and designated derivative contracts had notional amounts totaling approximately $ 31,178 and $ 3,219 , respectively, and $ 20,644 and $ 4,540 , respectively. These contracts were comprised of offsetting contracts with the same counterparty, each expire within one to six months . During the six months ended June 30, 2023 and 2022 , these contracts had, net of tax, an unrealized gain of $ 7 and an unrealized loss of $ 672 , respectively. The nonperformance risk of the Company and the counterparty did not have a material impact on the fair value of the derivatives. During the six months ended June 30, 2023 , there were no ineffective portions relating to these hedges and the hedges remained effective through their respective settlement dates. During the six months ended June 30, 2022, there were three ineffective portions relation to these hedges. As of June 30, 2023 , the Company had six designated hedges and four non-designated hedges. As of June 30, 2022 , the Company had three designated hedges and four non-designated hedges.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent events On July 10, 2023 , the Company entered into a share purchase agreement to acquire Physio-Assist SAS for approximately $ 32,000 in cash at closing and up to $ 13,000 in potential earn-out payment based on future regulatory clearances. Physio-Assist SAS, directly and through its wholly owned subsidiary, PhysioAssist GmbH, is in the business of the design, production and marketing of medical devices for bronchial decongestion (airway clearance technique) for patients suffering from obstructive respiratory diseases. The closing of the transaction is subject to certain customary closing conditions. The Company entered into an assignment and assumption of lease agreement for the lease of its current corporate headquarters on July 13, 2023. The assignment of the lease will be effective upon the completion of certain conditions. The Company entered into an additional operating lease on August 2, 2023 for its new corporate headquarters that has not yet commenced, with total minimum lease payments of $ 1,292 . This operating lease is estimated to commence in September 2023 with a lease term of approximately 4 years.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Consolidation	Basis of consolidation The consolidated financial statements include the accounts of Inogen, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of goodwill, impairment of long-lived assets, stock-based compensation expense, and income taxes. Actual results could differ from these estimates.
Restructuring charges	Restructuring charges Restructuring costs include workforce reductions, termination benefits, centralizing manufacturing activities, outsourcing, contract termination, and equipment relocation. Key assumptions used in calculating the restructuring costs include the terms of, and payments under, agreements to terminate certain contractual obligations and the timing of reductions in workforce

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Fair Value Assets Measured on Recurring Basis for Cash, Cash Equivalents and Marketable Securities	The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis for cash, cash equivalents and marketable securities: As of June 30, 2023 Gross Cash Adjusted unrealized and cash Marketable cost gains Fair value equivalents securities Cash $ 27,692 $ — $ 27,692 $ 27,692 $ — Level 1: Money market accounts 99,504 — 99,504 99,504 — Level 2: U.S. Treasury securities 22,218 160 22,378 19,919 2,459 Institutional Insured Liquidity Deposit Savings 20,572 — 20,572 20,572 — Total $ 169,986 $ 160 $ 170,146 $ 167,687 $ 2,459 As of December 31, 2022 Gross Cash Adjusted unrealized and cash cost gains Fair value equivalents Cash $ 27,970 $ — $ 27,970 $ 27,970 Level 1: Money market accounts 113,534 — 113,534 113,534 Level 2: Corporate bonds 6,474 — 6,474 6,474 U.S. Treasury securities 18,913 26 18,939 18,939 Institutional Insured Liquidity Deposit Savings 20,097 — 20,097 20,097 Total $ 186,988 $ 26 $ 187,014 $ 187,014
Summary of Components of Accumulated Other Comprehensive Income (Loss)	The components of accumulated other comprehensive income (loss) were as follows: Foreign Unrealized Unrealized Accumulated currency gains gains other translation on marketable on cash comprehensive adjustments securities flow hedges income (loss) Balance as of December 31, 2022 $ ( 269 ) $ 26 $ — $ ( 243 ) Other comprehensive income 177 133 7 317 Balance as of June 30, 2023 $ ( 92 ) $ 159 $ 7 $ 74

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Short-term Investments	Cash, cash equivalents and marketable securities consist of the following: June 30, December 31, Cash and cash equivalents 2023 2022 Cash $ 27,692 $ 27,970 Money market accounts 99,504 113,534 Corporate bonds — 6,474 U.S. Treasury securities 19,919 18,939 Institutional Insured Liquidity Deposit Savings 20,572 20,097 Total cash and cash equivalents $ 167,687 $ 187,014 Marketable securities U.S. Treasury securities 2,459 — Total marketable securities $ 2,459 $ —
Schedule of Net Accounts Receivable Balance Concentrations by Major Category	Net accounts receivable (gross accounts receivable, net of allowances) balance concentrations by major category as of June 30, 2023 and December 31, 2022 were as follows: June 30, December 31, Net accounts receivable 2023 2022 Rental (1) $ 5,886 $ 5,246 Business-to-business and other receivables (2) 45,249 57,479 Total net accounts receivable $ 51,135 $ 62,725 (1) Rental includes Medicare, Medicaid/other government, private insurance and patient pay. (2) Business-to-business receivables included extended terms for two customers: 1) One customer had accounts receivable balances of $ 5,878 and $ 9,861 as of June 30, 2023 and December 31, 2022 , respectively. The customer received extended payment terms through a direct financing plan offered. The Company also has a credit insurance policy in place, which allocated up to $ 12,000 in coverage as of June 30, 2023 and December 31, 2022 , for this customer with a $ 400 deductible and 10 % retention; and 2) One customer had an accounts receivable balance of $ 14,421 and $ 22,641 as of June 30, 2023 and December 31, 2022 .
Schedule of Allowances for Accounts Receivable	The following table sets forth the accounts receivable allowances as of June 30, 2023 and December 31, 2022: June 30, December 31, Allowances - accounts receivable 2023 2022 Doubtful accounts $ 236 $ 77 Sales returns 684 483 Total allowances - accounts receivable $ 920 $ 560
Breakdown of Company's Revenue from U.S. and Non-U.S. Sources	A portion of revenue is earned from sales outside the United States. Approximately 80.0 % and 77.4 % of the non-U.S. revenue for the three months ended June 30, 2023 and 2022 , respectively, were invoiced in Euros. Approximately 78.7 % and 75.6 % of the non-U.S. revenue for the six months ended June 30, 2023 and 2022, respectively, were invoiced in Euros. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the three and six months ended June 30, 2023 and 2022, respectively, is as follows: Three months ended Six months ended 2023 2022 2023 2022 U.S. revenue $ 60,343 $ 65,935 $ 113,533 $ 118,379 Non-U.S. revenue 23,292 37,441 42,264 65,382 Total revenue $ 83,635 $ 103,376 $ 155,797 $ 183,761
Schedule of Inventories	Inventories that are considered current consist of the following: June 30, December 31, 2023 2022 Raw materials and work-in-progress $ 22,100 $ 26,496 Finished goods 10,231 9,324 Less: reserves ( 1,587 ) ( 1,727 ) Inventories, net $ 30,744 $ 34,093
Summary of Depreciation and Amortization Expense of Rental Equipment and Other Property and Equipment	Depreciation and amortization expense related to rental equipment and other property and equipment are summarized below for the three and six months ended June 30, 2023 and 2022, respectively. Three months ended Six months ended 2023 2022 2023 2022 Rental equipment $ 3,238 $ 2,720 $ 6,316 $ 5,358 Other property and equipment 1,017 978 1,999 1,953 Total depreciation and amortization $ 4,255 $ 3,698 $ 8,315 $ 7,311
Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation	Property and equipment and rental equipment with associated accumulated depreciation is summarized below as of June 30, 2023 and December 31, 2022, respectively. June 30, December 31, Property and equipment 2023 2022 Rental equipment, net of allowances of $ 2,885 and $ 2,255 , respectively $ 65,603 $ 61,679 Other property and equipment 36,494 33,434 Property and equipment 102,097 95,113 Accumulated depreciation Rental equipment 30,535 31,320 Other property and equipment 22,367 20,524 Accumulated depreciation 52,902 51,844 Property and equipment, net Rental equipment, net of allowances of $2,885 and $2,255, respectively 35,068 30,359 Other property and equipment 14,127 12,910 Property and equipment, net $ 49,195 $ 43,269
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the six months ended June 30, 2023 were as follows: Balance as of December 31, 2022 $ 32,852 Translation adjustment 37 Balance as of June 30, 2023 $ 32,889
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, 2023 2022 Accounts payable $ 13,389 $ 18,237 Accrued inventory (in-transit and unvouchered receipts) and trade payables 7,913 10,837 Accrued purchasing card liability 4,065 2,606 Accrued franchise, sales and use taxes 482 492 Other accrued expenses 1,763 1,802 Accounts payable and accrued expenses $ 27,612 $ 33,974
Schedule of Accrued Payroll	Accrued payroll as of June 30, 2023 and December 31, 2022 consisted of the following: June 30, December 31, 2023 2022 Accrued bonuses $ 1,661 $ 2,620 Accrued wages and other payroll related items 5,664 4,967 Accrued vacation 3,099 3,133 Accrued employee stock purchase plan deductions 411 470 Accrued payroll $ 10,835 $ 11,190

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Right-of-Use Assets and Operating Lease Liabilities	Information related to the Company's right-of-use assets and related operating lease liabilities were as follows: Six months ended June 30, 2023 2022 Cash paid for operating lease liabilities $ 1,986 $ 1,994 Operating lease cost 1,920 1,932 Non-cash right-of-use assets obtained in exchange for new operating lease obligations 264 225 Weighted average remaining lease term 2.0 years 2.7 years Weighted average discount rate 3.0 % 2.9 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities due in the 12-month period ending June 30, 2024 $ 4,030 2025 3,149 2026 2,778 2027 2,813 2028 2,845 Thereafter 7,967 23,582 Less imputed interest ( 1,703 ) Total lease liabilities $ 21,879 Operating lease liability - current $ 3,622 Operating lease liability - noncurrent $ 18,257 Total lease liabilities $ 21,879

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Computation of Earnings Per Share	The computation of EPS is as follows: Three months ended Six months ended 2023 2022 2023 2022 Numerator—basic and diluted: Net loss $ ( 9,826 ) $ ( 3,442 ) $ ( 30,175 ) $ ( 17,656 ) Denominator: Weighted average common shares - basic common stock (1) 23,146,117 22,845,040 23,078,244 22,799,981 Weighted average common shares - diluted common stock (2) 23,146,117 22,845,040 23,078,244 22,799,981 Net loss per share - basic common stock $ ( 0.42 ) $ ( 0.15 ) $ ( 1.31 ) $ ( 0.77 ) Net loss per share - diluted common stock (2) $ ( 0.42 ) $ ( 0.15 ) $ ( 1.31 ) $ ( 0.77 ) Denominator calculation from basic to diluted: Weighted average common shares - basic common stock (1) 23,146,117 22,845,040 23,078,244 22,799,981 Stock options and other dilutive awards 90,017 93,181 211,114 127,759 Weighted average common shares - diluted common stock 23,236,134 22,938,221 23,289,358 22,927,740 Shares excluded from diluted weighted average shares: Stock options 54,498 325,734 54,498 325,734 Restricted stock units and restricted stock awards 1,209,475 509,785 377,931 503,435 Shares excluded from diluted weighted average shares 1,263,973 835,519 432,429 829,169 (1) Unvested restricted stock units and restricted stock awards are not included as shares outstanding in the calculation of basic earnings per share. Vested restricted stock units and restricted stock awards are included in basic earnings per share if all vesting and performance criteria have been met. Performance-based restricted stock units and restricted stock awards are included in the number of shares used to calculate diluted earnings per share as long as all applicable performance criteria are met, and their effect is dilutive. Restricted stock awards are eligible to receive all dividends declared on the Company’s common shares during the vesting period; however, such dividends are not paid until the restrictions lapse. (2) Due to net losses for the three and six months ended June 30, 2023 and June 30, 2022 , diluted loss per share is the same as basic.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Summary of Stock Options Activity	The activity for stock options under the Company’s stock plans for the six months ended June 30, 2023 is as follows: Remaining weighted- Weighted- average Per share average contractual average Price per exercise terms intrinsic Options share price (in years) value Outstanding as of December 31, 2022 348,284 $ 1.17 -$ 83.30 $ 44.21 0.43 $ 2.07 Exercised ( 54,432 ) 1.17 - 8.37 7.03 Forfeited ( 4,125 ) 44.19 44.19 Expired ( 232,363 ) 44.19 44.19 Outstanding as of June 30, 2023 57,364 8.37 - 83.30 79.56 0.57 0.16 Vested and exercisable as of June 30, 2023 57,364 8.37 - 83.30 79.56 0.57 0.16 Vested and expected to vest as of June 30, 2023 57,364 $ 8.37 -$ 83.30 $ 79.56 0.57 $ 0.16
Summary of Restricted Stock Activity	Stock Awards activity for the six months ended June 30, 2023 is summarized below: Weighted- average grant Performance date fair and value Restricted stock units Time-based time-based Total per share Unvested restricted stock units as of December 31, 2022 820,941 183,197 1,004,138 $ 32.72 Granted 855,708 536,990 1,392,698 15.11 Vested ( 167,044 ) ( 15,618 ) ( 182,662 ) 35.32 Forfeited/canceled ( 214,852 ) ( 73,185 ) ( 288,037 ) 25.97 Unvested restricted stock units as of June 30, 2023 (1) 1,294,753 631,384 1,926,137 $ 21.20 Unvested and expected to vest restricted stock units outstanding as of June 30, 2023 1,369,435 $ 21.64 Weighted- average grant Performance date fair and value Restricted stock awards Time-based time-based Total per share Unvested restricted stock awards outstanding as of December 31, 2022 786 — 786 $ 59.55 Vested ( 786 ) — ( 786 ) 59.55 Unvested restricted stock awards outstanding as of June 30, 2023 (1) — — — $ — Unvested and expected to vest restricted stock awards outstanding as of June 30, 2023 — $ — (1) Outstanding restricted stock units and restricted stock awards are based on the maximum payout of the targeted number of shares.
Summary of Stock-based Compensation Expense	Stock-based compensation expense recognized for the three and six months ended June 30, 2023 and 2022, was as follows: Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 Stock-based compensation expense by type of award: Restricted stock units and restricted stock awards $ 3,177 $ 2,891 $ 6,482 $ 5,359 Employee stock purchase plan 86 129 223 326 Total stock-based compensation expense $ 3,263 $ 3,020 $ 6,705 $ 5,685 For the three and six months ended June 30, 2023 and 2022, respectively, stock-based compensation expense recognized under ASC 718, included in cost of revenue, research and development expense, sales and marketing expense, and general and administrative expense was as follows: Three months ended Six months ended June 30, June 30, 2023 2022 2023 2022 Cost of revenue $ 153 $ 303 $ 237 $ 536 Research and development 376 412 834 796 Sales and marketing 658 766 1,432 1,357 General and administrative 2,076 1,539 4,202 2,996 Total stock-based compensation expense $ 3,263 $ 3,020 $ 6,705 $ 5,685

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Changes in Aggregate Product Warranty Liabilities	The following table identifies the changes in the Company’s aggregate product warranty liabilities for the six and twelve-month periods ended June 30, 2023 and December 31, 2022, respectively: June 30, December 31, 2023 2022 Product warranty liability at beginning of period $ 19,913 $ 13,726 Accruals for warranties issued 4,241 10,416 Adjustments related to preexisting warranties 2,817 8,234 Settlements made (in cash or in kind) ( 5,773 ) ( 12,463 ) Product warranty liability at end of period $ 21,198 $ 19,913

Business Overview - Additional

Business Overview - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Inogen Europe Holding B.V.
Business Overview Disclosures [Line Items]
Date of incorporation of subsidiary	Apr. 13, 2017

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis for Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 167,687	$ 187,014
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	169,986	186,988
Gross unrealized gains	160	26
Fair value	170,146	187,014
Cash and cash equivalents	167,687	187,014
Marketable securities	2,459
Fair Value Measurements Recurring | Cash
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	27,692	27,970
Fair value	27,692	27,970
Cash and cash equivalents	27,692	27,970
Fair Value Measurements Recurring | Level 1 | Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	99,504	113,534
Fair value	99,504	113,534
Cash and cash equivalents	99,504	113,534
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost		6,474
Fair value		6,474
Cash and cash equivalents		6,474
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	22,218	18,913
Gross unrealized gains	160	26
Fair value	22,378	18,939
Cash and cash equivalents	19,919	18,939
Marketable securities	2,459
Fair Value Measurements Recurring | Fair Value, Inputs, Level 2 | Institutional Insured Liquidity Deposit Savings
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Adjusted cost	20,572	20,097
Fair value	20,572	20,097
Cash and cash equivalents	$ 20,572	$ 20,097

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Forward Contracts
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Related payable	$ 179	$ 422

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	$ 281,297	$ 358,285	$ 297,406	$ 370,227
Other comprehensive income	78	(1,225)	317	(1,510)
Ending Balance	274,779	356,537	274,779	356,537
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance			(269)
Other comprehensive income			177
Ending Balance	(92)		(92)
Unrealized Gains on Marketable Securities
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance			26
Other comprehensive income			133
Ending Balance	159		159
Unrealized Gains (Losses) on Cash Flow Hedges
Accumulated Other Comprehensive Income Loss [Line Items]
Other comprehensive income			7
Ending Balance	7		7
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(4)	1,184	(243)	1,469
Other comprehensive income	78	(1,225)	317	(1,510)
Ending Balance	$ 74	$ (41)	$ 74	$ (41)

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Cash, Cash Equivalents and Short-term Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash and cash equivalents
Cash	$ 27,692	$ 27,970
Money market accounts	99,504	113,534
Corporate bonds		6,474
U.S. Treasury securities	19,919	18,939
Institutional Insured Liquidity Deposit Savings	20,572	20,097
Total cash and cash equivalents	167,687	$ 187,014
Marketable securities
Marketable securities	2,459
U.S. Treasury Securities
Marketable securities
Marketable securities	$ 2,459

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Net Accounts Receivable Balance Concentrations by Major Category (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	$ 51,135	$ 62,725
Rental
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	5,886	5,246
Business To Business And Other Receivables
Accounts Notes And Loans Receivable [Line Items]
Net accounts receivable	$ 45,249	$ 57,479

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Net Accounts Receivable Balance Concentrations by Major Category (Parenthetical) (Details) - Customer Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($) Customer	Dec. 31, 2022 USD ($)
Business To Business Receivables
Accounts Notes And Loans Receivable [Line Items]
Number of customers | Customer	2
Gross accounts receivable	$ 5,878,000	$ 9,861,000
Credit insurance policy, deductible amount	$ 400,000	$ 400,000
Credit insurance policy, retention percentage	10%	10%
Business To Business Receivables | Maximum
Accounts Notes And Loans Receivable [Line Items]
Credit insurance policy, coverage limit	$ 12,000,000	$ 12,000,000
Business To Business Receivables One
Accounts Notes And Loans Receivable [Line Items]
Gross accounts receivable	$ 14,421,000	$ 22,641,000

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Allowances for Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Doubtful accounts	$ 236	$ 77
Sales returns	684	483
Total allowances - accounts receivable	$ 920	$ 560

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Customer	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) Customer
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	$ 51,135,000		$ 51,135,000		$ 62,725,000
Percentage of Non-US revenue invoiced in Euros	80%	77.40%	78.70%	75.60%
Transfer of inventory to rental equipment			$ 1,567,000	$ 692,000
Repairs and maintenance expense	$ 1,241,000	$ 1,201,000	2,553,000	2,230,000
Impairments of long-lived assets			0	$ 0
Goodwill impairment loss			0
Other Noncurrent Assets
Schedule Of Balance Sheet Components [Line Items]
Noncurrent inventories expected to be realized or consumed	1,087,000		1,087,000		1,249,000
Prepaid Expenses and Other Current Assets
Schedule Of Balance Sheet Components [Line Items]
Inventory raw materials	2,369,000		2,369,000		7,017,000
Customer Concentration Risk | Customer One
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	14,421,000		14,421,000		22,641,000
Customer Concentration Risk | Customer Two
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	5,878,000		5,878,000		9,861,000
Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Accounts receivable, net	$ 2,143,000		$ 2,143,000		$ 2,138,000
Sales Revenue, Net | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			14.60%	11.60%
Net Accounts Receivable | Customer Concentration Risk
Schedule Of Balance Sheet Components [Line Items]
Number of customers | Customer			2		2
Net Accounts Receivable | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			4.20%		3.40%
Rental Revenue | Customer Concentration Risk | Medicare's Service Reimbursement Programs
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			72.10%	78.50%
Raw materials | Supplier Concentration Risk | Vendor one
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			30.10%	24.40%
Raw materials | Supplier Concentration Risk | Vendor two
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			14.50%	22.30%
Raw materials | Supplier Concentration Risk | Vendor three
Schedule Of Balance Sheet Components [Line Items]
Concentration Risk, Percentage			11%	8.80%

Balance Sheet Components - Brea

Balance Sheet Components - Breakdown of the Company Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Revenues	$ 83,635	$ 103,376	$ 155,797	$ 183,761
U.S. revenue
Concentration Risk [Line Items]
Revenues	60,343	65,935	113,533	118,379
Non-U.S. revenue
Concentration Risk [Line Items]
Revenues	$ 23,292	$ 37,441	$ 42,264	$ 65,382

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials and work-in-progress	$ 22,100	$ 26,496
Finished goods	10,231	9,324
Less: reserves	(1,587)	(1,727)
Inventories, net	$ 30,744	$ 34,093

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Depreciation and Amortization Expense of Rental Equipment and Other Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property Plant And Equipment [Line Items]
Depreciation	$ 3,238	$ 2,720	$ 6,316	$ 5,358
Depreciation and amortization	4,255	3,698	8,315	7,311
Rental equipment
Property Plant And Equipment [Line Items]
Depreciation	3,238	2,720	6,316	5,358
Other property and equipment
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 1,017	$ 978	$ 1,999	$ 1,953

Balance Sheet Components - Su_3

Balance Sheet Components - Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment	$ 102,097	$ 95,113
Accumulated depreciation	52,902	51,844
Property and equipment, net	49,195	43,269
Rental equipment
Property Plant And Equipment [Line Items]
Property and equipment	65,603	61,679
Accumulated depreciation	30,535	31,320
Property and equipment, net	35,068	30,359
Other property and equipment
Property Plant And Equipment [Line Items]
Property and equipment	36,494	33,434
Accumulated depreciation	22,367	20,524
Property and equipment, net	$ 14,127	$ 12,910

Balance Sheet Components - Su_4

Balance Sheet Components - Summary of Property Plant and Equipment and Rental Equipment with Associated Accumulated Depreciation (Parenthetical) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Rental equipment, allowance	$ 2,885	$ 2,255

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance as of December 31, 2022	$ 32,852
Translation adjustment	37
Balance as of June 30, 2023	$ 32,889

Balance Sheet Components - Sc_6

Balance Sheet Components - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 13,389	$ 18,237
Accrued inventory (in-transit and unvouchered receipts) and trade payables	7,913	10,837
Accrued purchasing card liability	4,065	2,606
Accrued franchise, sales and use taxes	482	492
Other accrued expenses	1,763	1,802
Accounts payable and accrued expenses	$ 27,612	$ 33,974

Balance Sheet Components - Sc_7

Balance Sheet Components - Schedule of Accrued Payroll (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued bonuses	$ 1,661	$ 2,620
Accrued wages and other payroll related items	5,664	4,967
Accrued vacation	3,099	3,133
Accrued employee stock purchase plan deductions	411	470
Accrued payroll	$ 10,835	$ 11,190

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lessee Lease Description [Line Items]
Operating lease, option to extend			options to extend the leases for up to 5 years.
Operating lease, existence of option to extend [true false]			true
Rent expense, including short-term lease cost	$ 964	$ 958	$ 1,936	$ 1,929
Minimum
Lessee Lease Description [Line Items]
Operating leases, lease term	3 years		3 years
Maximum
Lessee Lease Description [Line Items]
Operating leases, lease term	11 years		11 years
Operating lease option to extend term			5 years

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Cash paid for operating lease liabilities	$ 1,986	$ 1,994
Operating lease cost	1,920	1,932
Non-cash right-of-use assets obtained in exchange for new operating lease obligations	$ 264	$ 225
Weighted average remaining lease term	2 years	2 years 8 months 12 days
Weighted average discount rate	3%	2.90%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Maturities of lease liabilities due in the 12-month period ending March 31,
2024	$ 4,030
2025	3,149
2026	2,778
2027	2,813
2028	2,845
Thereafter	7,967
Operating lease liabilities payments due	23,582
Less imputed interest	(1,703)
Total lease liabilities	21,879
Operating lease liability - current	3,622	$ 3,515
Operating lease liability - noncurrent	$ 18,257	$ 19,764

Earnings (Loss) per Share - Com

Earnings (Loss) per Share - Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator—basic and diluted:
Net loss	$ (9,826)	$ (3,442)	$ (30,175)	$ (17,656)
Denominator:
Weighted average common shares - basic common stock	23,146,117	22,845,040	23,078,244	22,799,981
Weighted average common shares - diluted common stock	23,146,117	22,845,040	23,078,244	22,799,981
Net loss per share - basic common stock	$ (0.42)	$ (0.15)	$ (1.31)	$ (0.77)
Net loss per share - diluted common stock	$ (0.42)	$ (0.15)	$ (1.31)	$ (0.77)
Denominator calculation from basic to diluted:
Weighted average common shares - basic common stock	23,146,117	22,845,040	23,078,244	22,799,981
Stock options and other dilutive awards	90,017	93,181	211,114	127,759
Weighted average common shares - diluted common stock	23,236,134	22,938,221	23,289,358	22,927,740
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	1,263,973	835,519	432,429	829,169
Stock options
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	54,498	325,734	54,498	325,734
Restricted stock units and restricted stock awards
Shares excluded from diluted weighted average shares:
Shares excluded from diluted weighted-average shares	1,209,475	509,785	377,931	503,435

Income taxes - Additional Infor

Income taxes - Additional Information (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Valuation allowance	$ 41,933

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 05, 2023	Jun. 04, 2023
Class Of Stock [Line Items]
Total intrinsic value of options exercised	$ 735	$ 204
Time based restricted stock units
Class Of Stock [Line Items]
Vesting period	4 years
Time based restricted stock awards
Class Of Stock [Line Items]
Vesting period	4 years
Performance and time based restricted stock awards
Class Of Stock [Line Items]
Vesting period	3 years
Performance and time based restricted stock units
Class Of Stock [Line Items]
Vesting period	3 years
Restricted stock units and restricted stock awards
Class Of Stock [Line Items]
Stock option shares outstanding	1,980,633
Unrecognized compensation cost related to unvested employee excluding estimated forfeitures	$ 23,037
Amount expected to recognized over weighted-average period	2 years 2 months 12 days
Maximum | Stock options
Class Of Stock [Line Items]
Stock option period, expiration	10 years
Vesting period	4 years
Minimum | Stock options
Class Of Stock [Line Items]
Stock option period, expiration	7 years
Vesting period	1 year
2012 Plan
Class Of Stock [Line Items]
Stock option shares outstanding	2,866
Number of equity awards available for grant	0
2014 Share Reserve Plan
Class Of Stock [Line Items]
Number of equity awards available for grant	895,346
2014 ESPP Plan
Class Of Stock [Line Items]
Number of equity awards available for grant	638,951
Terms of shares available for issuance	The number of shares available for sale under the ESPP is increased annually on the first day of each fiscal year by an amount equal to the least of:•179,069 shares;•1.5% of the outstanding shares of the Company’s common stock on the last day of the Company’s immediately preceding fiscal year; or•such other amount as may be determined by the administrator.
Percentage on outstanding shares of common stock	1.50%
Number of additional number of shares reserve to provision	179,069
Maximum percentage of common stock eligible to purchase through payroll deductions for participants	15%
Maximum number of shares available for participant to purchase during period	1,500
Purchase price as percentage of stock price on offering period	85%
Purchase price as percentage of stock price on exercise date	85%
Potential increase of shares available for issuance	179,069
2023 Plan
Class Of Stock [Line Items]
Number of equity awards available for grant	1,255,532
Number of shares common stock reserved for issuance			400,000
2023 Plan | Maximum
Class Of Stock [Line Items]
Stock option shares outstanding			2,950,000
2014 Plan
Class Of Stock [Line Items]
Number of shares common stock reserved for issuance				2,027,790

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Stock Options Outstanding, Beginning balance	348,284
Stock Options, Exercised	(54,432)
Stock Options, Forfeited	(4,125)
Stock Options, Expired	(232,363)
Stock Options Outstanding, Ending balance	57,364	348,284
Stock Options, Vested and exercisable	57,364
Stock Options, Vested and expected to vest	57,364
Price per share, Forfeited	$ 44.19
Price per share, Expired	44.19
Outstanding, Weighted-average exercise price, Beginning balance	44.21
Weighted-average exercise price, Exercised	7.03
Weighted-average exercise price, Forfeited	44.19
Weighted-average exercise price, Expired	44.19
Outstanding, Weighted-average exercise price, Ending balance	79.56	$ 44.21
Weighted-average exercise price, Vested and exercisable	79.56
Weighted-average exercise price, Vested and expected to vest	$ 79.56
Remaining weighted-average contractual term, Outstanding	6 months 25 days	5 months 4 days
Remaining weighted-average contractual term, Vested and exercisable	6 months 25 days
Remaining weighted-average contractual term, Vested and expected to vest	6 months 25 days
Outstanding, Per share average intrinsic value	$ 0.16	$ 2.07
Per share average intrinsic value, Vested and exercisable	0.16
Per share average intrinsic value, Vested and expected to vest	0.16
Minimum
Class Of Stock [Line Items]
Outstanding, Price per share, Beginning balance	1.17
Price per share, Exercised	1.17
Outstanding, Price per share, Ending balance	8.37	1.17
Price per share, Vested and exercisable	8.37
Price per share, Vested and expected to vest	8.37
Maximum
Class Of Stock [Line Items]
Outstanding, Price per share, Beginning balance	83.3
Price per share, Exercised	8.37
Outstanding, Price per share, Ending balance	83.3	$ 83.3
Price per share, Vested and exercisable	83.3
Price per share, Vested and expected to vest	$ 83.3

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Activity (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Time based restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	820,941
Granted	855,708
Vested	(167,044)
Forfeited/canceled	(214,852)
Unvested restricted stock units/ awards outstanding, Ending balance	1,294,753
Performance and time based restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	183,197
Granted	536,990
Vested	(15,618)
Forfeited/canceled	(73,185)
Unvested restricted stock units/ awards outstanding, Ending balance	631,384
Restricted stock units
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	1,004,138
Granted	1,392,698
Vested	(182,662)
Forfeited/canceled	(288,037)
Unvested restricted stock units/ awards outstanding, Ending balance	1,926,137
Unvested and expected to vest restricted stock units/awards outstanding	1,369,435
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Beginning balance | $ / shares	$ 32.72
Weighted-average grant date fair value per share, Granted | $ / shares	15.11
Weighted-average grant date fair value per share, Vested | $ / shares	35.32
Weighted-average grant date fair value per share, Forfeited/canceled | $ / shares	25.97
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Ending balance | $ / shares	21.2
Weighted-average grant date fair value per share, Unvested and expected to vest restricted stock units/awards outstanding | $ / shares	$ 21.64
Time based restricted stock awards
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	786
Vested	(786)
Restricted stock awards
Class Of Stock [Line Items]
Unvested restricted stock units/ awards outstanding, Beginning balance	786
Vested	(786)
Weighted-average grant date fair value per share, Unvested restricted stock units/ awards outstanding, Beginning balance | $ / shares	$ 59.55
Weighted-average grant date fair value per share, Vested | $ / shares	$ 59.55

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock-based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock-based compensation expense by type of award:
Stock-based compensation expense	$ 3,263	$ 3,020	$ 6,705	$ 5,685
Restricted stock units and restricted stock awards
Stock-based compensation expense by type of award:
Stock-based compensation expense	3,177	2,891	6,482	5,359
Employee Stock Purchase Plan
Stock-based compensation expense by type of award:
Stock-based compensation expense	$ 86	$ 129	$ 223	$ 326

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Stock-based Compensation Expense Recognized in Income Statement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,263	$ 3,020	$ 6,705	$ 5,685
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	153	303	237	536
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	376	412	834	796
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	658	766	1,432	1,357
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,076	$ 1,539	$ 4,202	$ 2,996

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Outstanding purchase orders due within one year with its outside vendors and suppliers	$ 124,400
Payments received in advance of satisfying performance obligations	1,820
Revenue recognized	3,309
Lifetime Warranties | Direct-to-Consumer
Commitments And Contingencies [Line Items]
Deferred revenue related to life time warranties	$ 15,045	$ 16,534

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Changes in Aggregate Product Warranty Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Product warranty liability at beginning of period	$ 19,913	$ 13,726
Accruals for warranties issued	4,241	10,416
Adjustments related to preexisting warranties	2,817	8,234
Settlements made (in cash or in kind)	(5,773)	(12,463)
Product warranty liability at end of period	$ 21,198	$ 19,913

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring costs	$ 201	$ 2,010

Foreign Currency Exchange Con_2

Foreign Currency Exchange Contracts and Hedging - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) Contract	Jun. 30, 2022 USD ($) Contract
Derivatives Fair Value [Line Items]
Unrealized gain (loss) on derivative | $	$ 7,000	$ (672,000)
Number of contract ineffective hedges | Contract	0	3
Number of contract designated hedges | Contract	6	3
Number of contract non-designated hedges | Contract	4	4
Non-Designated Derivative Contracts
Derivatives Fair Value [Line Items]
Derivative contracts notional amounts | $	$ 31,178,000	$ 20,644,000
Designated Derivative Contracts
Derivatives Fair Value [Line Items]
Derivative contracts notional amounts | $	$ 3,219,000	$ 4,540,000
Minimum
Derivatives Fair Value [Line Items]
Derivative contracts expiration period	1 month
Maximum
Derivatives Fair Value [Line Items]
Derivative contracts expiration period	6 months

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent event - USD ($) $ in Thousands	Aug. 02, 2023	Jul. 10, 2023
Subsequent Event [Line Items]
Minimum lease payments	$ 1,292
Lease commencement period	2023-09
Operating lease term	4 years
Physio-Assist SAS | Share Purchase Agreement
Subsequent Event [Line Items]
Date of acquisition agreement		Jul. 10, 2023
Payments to acquire business		$ 32,000
Potential earn-out payment based on future regulatory clearances		$ 13,000